Higher baseline CD4 cell count predicts treatment interruptions and persistent viremia in patients initiating ARVs in rural uganda

Journal of Acquired Immune Deficiency Syndromes

Volumn 62, Issue 3, 2013, Pages 317-321

  Adakun, Susan A ^a   Siedner, Mark J ^b   Muzoora, Conrad ^a   Haberer, Jessica E ^b   Tsai, Alexander C ^b   Hunt, Peter W ^c   Martin, Jeff N ^c   Bangsberg, David R ^a,b  

^a MBARARA UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Uganda)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adherence; Adherence monitoring; HIV aids; MEMS; Test and treat; Uganda

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; RURAL POPULATION; SELF REPORT; VIREMIA;

EID: 85027928293     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182800daf     Document Type: Article

References (31)

1. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
2. Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010;363: 257-265.
3. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010:CD008272.
4. Sterne JA, May M, Costagliola D, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373:1352-1363.
5. Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.
6. Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373:48-57.
7. UNAIDS. Report on the Global AIDS Epidemic. Available at: http://www.unaids.org/GlobalReport/default.htm. Accessed November 1, 2011. 2010.
8. Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA. 2006; 296:679-690.
9. Yamano T, Jayne TS. Measuring the impacts of working-age adult mortality on small-scale farm households in Kenya. World Dev. 2004;32:91-119.
10. Nabyonga-Orem J, Bazeyo W, Okema A, et al. Effect of HIV/AIDS on household welfare in Uganda rural communities: a review. East Afr Med J. 2008;85:187-196.
11. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub- Saharan Africa: an ethnographic study. PLoS Med 2009;6:e11.
12. Baylies C. The impact of AIDS on rural households in Africa: a shock like any other? Dev Change. 2002;33:611-632.
13. Thirumurthy H, Zivin JG, Goldstein M. The economic impact of AIDS treatment labor supply in Western Kenya. J Hum Resour. 2008;43: 511-552.
14. Thirumurthy H, Jafri A, Srinivas G, et al. Two-year impacts on employment and income among adults receiving antiretroviral therapy in Tamil Nadu, India: a cohort study. AIDS. 2011;25:239-246.
15. Revicki DA, Sorensen S, Wu AW. Reliability and validity of physical and mental health summary scores from the Medical Outcomes Study HIV Health Survey. Med Care. 1998;36:126.
16. Bush K, Kivlahan DR, McDonell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory care quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification test. Arch Intern Med 1998;158:1789-1795.
17. Bolton P, Ndogoni L. Cross-cultural Assessment of Trauma-related Mental Illness (Phase II): A Report of Research Conducted by World Vision Uganda and the Johns Hopkins University. Baltimore, MD: The Johns Hopkins University; 2001.
18. Stangl A, Wamai N, Mermin J, et al. Trends and predictors of quality of life among HIV-infected adults taking highly active antiretroviral therapy in rural Uganda. AIDS Care. 2007;19:626-636.
19. Parienti JJ, Ragland K, Lucht F, et al. Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication. Clin Infect Dis. 2010;50: 1192-1197.
20. Filmer D, Pritchett LH. Estimating wealth effects without expenditure data-or tears: an application to educational enrollments in states of India. Demography. 2001;38:115-132.
21. Oyugi JH, Byakika-Tusiime J, Charlebois ED, et al. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. J Acquir Immune Defic Syndr. 2004;36:1100-1102.
22. Tsai AC, Bangsberg DR. The importance of social ties in sustaining medication adherence in resource-limited settings. J Gen Intern Med 2011;26:1391-1393.
23. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-2599.
24. Martin M, Vanichesni S, Suntharasamai P, et al. Participant adherence in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial in Bangkok. Paper presented at: 6th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention; July 17-20, 2011; Rome, Italy. [Abstract TUPE350].
25. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367: 411-422.
26. Haberer J, Baeten J, Celum C, et al. Near perfect early adherence to antiretroviral PrEP against HIV infection among HIV serodiscordant couples as determined by multiple measures: preliminary data from the partners PrEP study. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; February 27 - March 2, 2011; Boston, Massachusetts. Paper #488.
27. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012;367:399-410.
28. Genberg BL, Wilson IB, Bangsberg D, et al. Patterns of ART adherence and impact on HIV RNA among patients from the MACH14 study. AIDS. 2012;26:1415-1423.
29. Chung MH, Richardson BA, Tapia K, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med 2011;8: e1000422.
30. Pradier C, Bentz L, Spire B, et al. Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study. HIV Clin Trials. 2003;4:121-131.
31. Lester RT, Ritvo P, Mills EJ, et al. Effects of a mobile phone shortmessage service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838-1845.